Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Department of Immunopathology, Sanquin Research, Amsterdam , The Netherlands.
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L799-L809. doi: 10.1152/ajplung.00014.2018. Epub 2018 Aug 23.
Pneumonia is the most frequent cause of sepsis, and Klebsiella pneumoniae is a common pathogen in pneumonia and sepsis. Infection is associated with activation of the coagulation system. Coagulation can be activated by the extrinsic and intrinsic routes, mediated by factor VII (FVII) and factor XII (FXII), respectively. To determine the role of FVII and FXII in the host response during pneumonia-derived sepsis, mice were treated with specific antisense oligonucleotide (ASO) directed at FVII or FXII for 3 wk before infection with K. pneumoniae via the airways. FVII ASO treatment strongly inhibited hepatic FVII mRNA expression, reduced plasma FVII to ~25% of control, and selectively prolonged the prothrombin time. FXII ASO treatment strongly suppressed hepatic FXII mRNA expression, reduced plasma FXII to ~20% of control, and selectively prolonged the activated partial thromboplastin time. Lungs also expressed FVII mRNA, which was not altered by FVII ASO administration. Very low FXII mRNA levels were detected in lungs, which were not modified by FXII ASO treatment. FVII ASO attenuated systemic activation of coagulation but did not influence fibrin deposition in lung tissue. FVII ASO enhanced bacterial loads in lungs and mitigated sepsis-induced distant organ injury. FXII inhibition did not affect any of the host response parameters measured. These results suggest that partial inhibition of FVII, but not of FXII, modifies the host response to gram-negative pneumonia-derived sepsis.
肺炎是脓毒症最常见的病因,肺炎克雷伯菌是肺炎和脓毒症的常见病原体。感染与凝血系统的激活有关。凝血可以通过外源性和内源性途径激活,分别由因子 VII(FVII)和因子 XII(FXII)介导。为了确定 FVII 和 FXII 在肺炎相关性脓毒症宿主反应中的作用,在通过气道感染肺炎克雷伯菌之前,用针对 FVII 或 FXII 的特异性反义寡核苷酸(ASO)对小鼠进行 3 周的处理。FVII ASO 处理强烈抑制肝脏 FVII mRNA 表达,将血浆 FVII 降低至对照的约 25%,并选择性延长凝血酶原时间。FXII ASO 处理强烈抑制肝脏 FXII mRNA 表达,将血浆 FXII 降低至对照的约 20%,并选择性延长活化部分凝血活酶时间。肺组织也表达 FVII mRNA,但 FVII ASO 给药并未改变其表达。在肺组织中检测到极低水平的 FXII mRNA,FXII ASO 处理并未改变其表达。FVII ASO 减弱了全身凝血的激活,但不影响肺组织中的纤维蛋白沉积。FVII ASO 增加了肺部的细菌负荷,并减轻了脓毒症引起的远处器官损伤。FXII 抑制不影响所测量的任何宿主反应参数。这些结果表明,FVII 的部分抑制而不是 FXII 的抑制,可改变对革兰氏阴性肺炎相关性脓毒症的宿主反应。